Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma

Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities. The beneficiaries of adjuvant PD-1 inhibitors (aPD-1) and their efficacy across these temporally divergent recurrence patterns remains unestablished.

NCT Number	NCT07379489
Lead Sponsor	Tongji Hospital
Conditions	HCC, Adjuvant Therapy, Recurrence, Immune Checkpoint Inhibitor
Enrollment	300 participants
Start Date	2026-01-31
Primary Completion	2029-12-31 (estimated)
Study Completion	2031-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-30